

Grifols Announces US Launch of Flebogamma[®] 10% DIF IVIG

Building on the safety record of its 5% concentration, the new 10% liquid, room temperature IVIG preparation establishes Grifols as the only producer offering both 5% and 10% IVIG concentrations to healthcare providers and patients in the US.

Los Angeles, California (November 22, 2010). Grifols today announced availability of its recently approved Flebogamma[®] 10%DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma[®] 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement signals widespread product availability to the US market.

"We are excited about being able to meet a wider range of clinical needs by providing healthcare providers and patients the additional treatment option of Flebogamma[®] 10%DIF," said Gregory Rich, President of Grifols' US operations. "Grifols understands that the clinical needs of patients are unique and by offering a choice of IVIG concentrations we can better address them," continued Mr. Rich.

The approval and launch of Flebogamma[®] 5%DIF in early 2007, ushered in a new standard in IVIG treatment with the development of a dual inactivated, nano-filtered (DIF) product. Like Flebogamma[®] 5% DIF, the new 10% solution has two distinct

pathogen inactivation processes (heat treatment and solvent detergent) and a proprietary 20 nanometer filtration step. The manufacturing process for Flebogamma® DIF is also very efficient at eliminating extraneous proteins, resulting in a high purity IVIG solution (99.4% IgG). Development of the DIF production process was the result of more than a decade of research and the construction of dedicated, state-of-the-art IVIG production facilities in Barcelona, Spain. A twin production facility has been under construction in Los Angeles since 2008, and expected to be completed in 2013. For the time being, Grifols' Flebogamma® 10% DIF will be produced exclusively at its Barcelona facility.

“I commend Grifols on their commitment to the development of additional treatment options,” said Marcia Boyle, President and Founder of the Immune Deficiency Foundation, the national patient organization for persons with primary immune diseases. “New products help assure continued access to this lifesaving medicine so that countless people who live with primary immunodeficiencies, such as my son, can lead healthy and productive lives,” continued Ms. Boyle.

Like all Grifols' products, each vial of Flebogamma® 10% DIF is laser etched with a unique identification number to ensure product integrity. In addition, the outer packaging is secured with a tamper evident holographic overseal containing specialized printing to confirm authenticity. Grifols also offers healthcare providers access to a proprietary web-based system called PediGri® that provides full traceability for every plasma donation used to produce an individual product vial.

Grifols has a wholly owned dedicated engineering division (Grifols Engineering) that develops state-of-the-art manufacturing suites for the biologics industry. The design concepts used in the Flebogamma[®] 5% DIF and Flebogamma[®] 10% DIF production facility were developed exclusively by Grifols Engineering and include such things as minimal exposure zones to reduce manufacturing surface areas and the potential for microbial contamination. Process enhancements achieved by the use of newer technologies and Grifols' proprietary process design concepts result in an increase in the amount of IVIG that can be obtained from each plasma donation.

* * * *

About Grifols

Grifols S.A. is a Spain-based healthcare company engaged in the research, development, manufacturing and marketing of plasma therapies, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Grifols plasma therapies are produced from plasma obtained at over 80 donor centers across the US and are used to treat a variety of rare and life-threatening diseases. Founded in 1940, Grifols currently operates in 90 countries with more than 6,000 employees and 23 subsidiaries. Grifols is listed on the Ibex-35 Madrid stock exchange.

For more information about Grifols, please visit www.grifols.com or contact Chris Healey at (703) 351-5004.